Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer

BioDrugs · Published 2026-08-02 · DOI 10.1007/s40259-026-00800-1

Free full text

Authors (7)

Taekyung Kim, Heungjo Kim, Hongjae Lee, Keumyoung Ahn, Taehong Park, Hyungseok Baek, Min Jung Chang

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kim, T., Kim, H., Lee, H., et al. (2026). Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer. BioDrugs. https://doi.org/10.1007/s40259-026-00800-1

Related articles

• Population Pharmacokinetics of SCT510 (a Bevacizumab Biosimilar) and Avastin® in Healthy Subjects and Patients with Non-squamous Non-small Cell Lung Cancer · Clinical Drug Investigation · 2026 · Cites or is cited by this article
• mRNA Vaccines for Influenza: Hope for a Universal Vaccine? · BioDrugs · 2026 · Same journal
• Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability · BioDrugs · 2025 · Same journal
• Conditionally Activatable Antibody Platforms: Mechanisms, Modalities, and Clinical Translation Potential · BioDrugs · 2025 · Same journal
• Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics · BioDrugs · 2026 · Same journal
• Interleukin-23 Inhibitors in Inflammatory Bowel Disease · BioDrugs · 2026 · Same journal
• Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline · BioDrugs · 2025 · Same journal
• Site-Specific Genomic Markers Associated with Outcomes of PD-1 Blockade in Gastric and Esophagogastric Junction Cancer: Analysis of Japan’s C-CAT Registry · BioDrugs · 2026 · Same journal
• Individual Prescribing Incentives for Biosimilars in Selected European Countries and the USA: a Scoping Literature Review · BioDrugs · 2025 · Same journal
• Efficacy and Safety of Biosimilar AVT05 Versus Reference Product Golimumab in Combination with Methotrexate in Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results of a Randomized, Parallel-Group, Double-Blind Study · BioDrugs · 2025 · Same journal